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Abstract 48 
Introduction: Bipolar Disorder (BD) and Obsessive Compulsive Disorder (OCD) are prevalent, 49 
comorbid and disabling conditions, often characterized by early onset and chronic course. When 50 
comorbid, OCD and BD can determine a more pernicious course of illness, posing therapeutic 51 
challenges for clinicians. Available reports on prevalence and clinical characteristics of comorbidity 52 
between BD and OCD showed mixed results, likely depending on the primary diagnosis of 53 
analyzed samples.  54 
Methods: We assessed prevalence and clinical characteristics of BD comorbidity in a large 55 
International sample of patients with primary OCD (n=401), through the International College of 56 
Obsessive Compulsive Spectrum Disorders (ICOCS) snapshot database, by comparing OCD 57 
subjects with vs without BD comorbidity.  58 
Results: Amongst primary OCD patients, 6.2% showed comorbidity with BD. OCD patients with 59 
vs without BD comorbidity more frequently had a previous hospitalization (p<.001) and current 60 
augmentation therapies (p<.001). They also showed greater severity of OCD (p<.001), as measured 61 
by the Y-BOCS.  62 
Conclusion: These findings from a large International sample indicate that approximately 1 out of 63 
16 patients with primary OCD may additionally have BD comorbidity along with other specific 64 
clinical characteristics, including more frequent previous hospitalizations, more complex 65 
therapeutic regimens and a greater severity of OCD. Prospective international studies are needed to 66 
confirm our findings. 67 
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Introduction 69 
Obsessive Compulsive Disorder (OCD) and Bipolar Disorder (BD) are prevalent and chronic 70 
conditions, frequently comorbid, difficult-to-treat and highly disabling 1,2. Of note, both conditions 71 
have been separated into autonomous chapters by the DSM-5, respectively from anxiety disorders 72 
and depressive disorders, with other spectrum conditions included within the new chapters 3.  73 
While comorbidity in BD represents the rule rather than the exception, OCD seems to show lower - 74 
yet appreciable - rates of comorbidity, while mutual comorbidity (OCD+BD) prevalence was found 75 
to differ according to patients’ primary diagnosis 4. In a recent systematic review, patients with a 76 
primary OCD diagnosis showed rates of BD comorbidity ranging from 6 to 10%, while patients 77 
with primary BD were found to have comorbid OCD in 11 to 21% of the cases 4. However, given 78 
the traditionally early onset of both OCD and BDs, it is often difficult to assess which condition 79 
appeared first, family history being helpful - when positive - to help unraveling primary diagnosis 80 
along with subsequent longitudinal evaluations. 81 
Indeed, the presence of comorbidity between OCD and BD can determine a different course of 82 
illness, according to the primary diagnosis. For instance, in case of primary BD, OCD comorbidity 83 
was found to be associated with a more episodic course of OC symptoms, characterized by 84 
symptoms’ worsening during depression, symptoms’ improvement during mania/hypomania, and a 85 
higher mean number of depressive episodes 4,5 . On the other hand, in patients with primary OCD, 86 
the prescription of high doses of serotonergic antidepressants could induce mood elevation 87 
episodes, confounding in both cases situations of real vs spurious comorbidity 4–6. Comorbidity 88 
rates, moreover, may vary according to local (e.g., when detected in general psychiatric services vs 89 
tertiary clinics), clinical (severity of illness) and cultural variables (e.g., attitudes including stigma, 90 
secretiveness, access to treatment) 2. 91 
In the available literature, different studies addressed this topic, trying to better characterize this 92 
phenomenon and mutual influence of these disorders. Indeed, when primary BD is comorbid with 93 
OCD, the overall clinical condition may determine a more severe form of illness. In this respect, 94 
comorbid patients have been differently associated with relevant disease-related variables, like an 95 
earlier age at onset 7,8, higher frequency of residual symptoms 9, poorer functioning and poorer 96 
quality of life in different domains (i.e., lower GAF scale score 10, lower rate of employment in BDI 97 
patients 11), a higher rate of suicidal behavior 8,12,13. Moreover, additional comorbidity seemed to be 98 
higher in the comorbid group especially with anxiety disorders 7,9,11, alcohol 12 and substance abuse 99 
14, and with impulse control, eating, and tic disorders in BD female patients 9.  100 
Other studies specifically assessed the clinical characteristics of primary OCD patients with vs 101 
without BD comorbidity, reporting that comorbid patients present a worse clinical prognosis 102 
compared to non-comorbid patients, being associated with a higher suicidal risk 15, more frequent 103 
hospitalizations 16,17, more severe obsessive-compulsive symptoms according to Yale-Brown 104 
Obsessive Compulsive Scale (YBOCS) score 17, and a poorer response to treatments in a youth 105 
OCD sample 18. Moreover, an additional comorbid disease has been reported more frequently in 106 
these patients, in particular with alcohol 19 and substance abuse 17, and anxiety disorders 17,19. 107 
In light of the above, the aim of the present study was to assess rates and clinical correlates of BD 108 
comorbidity in a large, international sample of primary OCD patients, recruited in centers affiliated 109 
with the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). In 110 
particular, we hypothesized that BD comorbidity rates in the ICOCS sample could parallel 111 
previously reported rates in available studies of primary OCD patients, although the geographical 112 
diversity of the sample might also show distinct peculiarities in terms of epidemiology and clinical 113 
features. Moreover, based on the existing literature, we hypothesized that BD comorbid vs non 114 
comorbid OCD patients could show a higher burden of the disease, presenting specific clinical 115 
characteristics associated with a less favorable outcome like higher severity and related 116 
hospitalizations, a more frequent suicidal behavior, more complex therapeutic regimens, and a 117 
higher impact on social adaptation. 118 
 119 
Methods 120 
Among the whole ICOCS sample of 504 OCD outpatients, we selected and analyzed individuals 121 
having available information on bipolar comorbidity. The resulting sample of the present analysis 122 
consisted of 401 outpatients of either gender and any age, attending different OCD clinics 123 
worldwide, participating in the ICOCS network. Diagnoses were obtained using the Structured 124 
Clinical Interview for DSM-IV-TR Axis I disorders (SCID I) 20. After obtaining patients’ written 125 
informed consent and approval from local Ethic Committees/Institutional Review Boards for using 126 
patients’ information for research purposes, socio-demographic and clinical variables were 127 
collected and included in a common web database. Additional details about sample assessment have 128 
been published elsewhere 21. Suicidal behavior was assessed with Mini-International 129 
Neuropsychiatric Interview 22. 130 
In a previous ICOCS publication on comorbidity with OC-related and other psychiatric conditions 131 
in a slightly different sample (due to additional patients being recruited and the exclusion of other 132 
patients with missing data and incomplete information), BD comorbidity had not been evaluated, 133 
being set aside for a separate subsequent analysis and publication 1. 134 
For the purpose of the present study, patients were categorized into two subgroups based on the 135 
presence (OCD-wBD) or absence (OCD-w/oBD) of comorbidity with BD. The two subgroups were 136 
compared with respect to a series of socio-demographic and clinical variables specified in Table 1. 137 
Statistical analyses were performed with Pearson’s chi-squared test for categorical variables and t-138 
test for continuous ones. For all the analyses, the level of statistical significance was set at .05. 139 
 140 
Results 141 
Within the overall sample, 6.2% (n=32) of OCD patients had comorbidity with BD. Socio-142 
demographic and clinical variables of the two subgroups of OCD patients with vs without BD 143 
comorbidity are reported in Table 1. 144 
Figure 1 shows socio-demographic and clinical variables that were found to differ between the two 145 
subgroups. OCD patients with versus without BD comorbidity showed a higher rate of previous 146 
psychiatric hospitalization (48.2% vs 20.6%, p<.001) and a higher prevalence of augmentation 147 
therapies vs monotherapies (77.3% vs 48.5%, p<.001), being augmentation therapies those 148 
compounds used as add-on for treatment resistant OCD patients. More in detail, on both OCD 149 
subgroups, the most frequently prescribed augmentation therapies were antipsychotics (OCD-wBD 150 
66.7% and OCD-w/oBD 34.6%), being risperidone the most represented (OCD-wBD 42.2% and 151 
OCD-w/oBD 75%); given a high rate of missing data for these specific variables, both analysis did 152 
not reach a statistically significant threshold. 153 
Additionally, a significantly higher severity of OCD emerged in OCD patients with vs without BD 154 
comorbidity, as measured through the YBOCS 23 total scores (25.7 vs 22.5, p<.001), with no 155 
statistically significant differences in obsession (12.5 vs 11.5) and compulsion (12.1 vs 10.9) 156 
subscales.  157 
While differences in terms of suicide attempts between the two groups were not observed, current 158 
suicide risk showed as twice the rate in OCD patients with vs without BD comorbidity (31.3% vs 159 
14.6%), without reaching the statistically significant threshold. Lastly, OCD patients with vs 160 
without BD comorbidity were more frequently found to live alone (25% vs 13.8%), be divorced 161 
(10.3% vs 5.9%), and to be unemployed (15.6% vs 8.7%), although not a statistically significant 162 
level.  163 
 164 
Discussion 165 
In this ICOCS report, we focused on prevalence and clinical correlates of BD comorbidity in 166 
primary OCD patients. Our observed lifetime prevalence of BD comorbidity (6.2%) can be 167 
positioned at the lower range in relation to the available studies in the field 4. This is likely due to 168 
the composition of the ICOCS sample, constituted by primary OCD patients attending tertiary OCD 169 
clinics worldwide, and to the fact that patients with a comorbid BD diagnosis are more frequently 170 
referred to community psychiatric centers or BD specialized centers. Additionally, this result might 171 
derive from the limited overall comorbidity rate (35%) characterizing our sample. BD comorbidity, 172 
therefore, appears to be less frequent in primary OCD patients than is OCD comorbidity in primary 173 
BD patients. In this respect, previous International reports showed a higher rate of other comorbid 174 
DSM-IV-TR Axis I disorders, compared to BD, with major depressive disorder and 175 
anxiety disorders being the most common comorbid conditions in primary OCD patients 1,24. 176 
The higher rate of previous hospitalization in the comorbid cases seems to be consistent with 177 
previous reports 4,17,19,25,26 and may likely be determined by the co-occurrence of BD episodes, 178 
causing more frequent admission to hospital (following severe manic or depressive episodes), even 179 
though it may also be related to OCD worsening due to a higher severity of OCD in comorbid 180 
patients (as suggested by the greater severity of illness confirmed by the Y-BOCS in these 181 
individuals). 182 
The more complex psychopharmacological regimen observed in OCD with vs without BD 183 
comorbidity, reflecting a higher rate of augmentation treatments vs monotherapies in the former 184 
group, may also be interpreted as a characteristic of greater severity of OCD and overall illness, 185 
making it necessary to frequently add an antipsychotic to the serotonergic reuptake inhibitor (SRI), 186 
due to the severe nature of OC symptoms and in order to prevent manic switches 27. The same result 187 
was reported in a study with young OCD subjects, where comorbid OCD+BD patients showed a 188 
more frequently poly-therapy compared to a SRIs only therapy, with second generation 189 
antipsychotics, including risperidone, most prevalently used in the comorbid group 28. Literature 190 
data support Risperidone efficacy as augmentative therapy over SRI alone in OCD resistant patients 191 
29,30 particularly in those patients with a history of mood instability 31, emphasizing Risperidone 192 
potential pharmacological effect on mood stabilization. Nonetheless, OCD comorbid patients could 193 
have received more frequently augmentation therapies just for the occurrence of two diagnoses, 194 
each one requiring a different therapeutic regimen. Of note, no significant differences emerged with 195 
respect to cognitive behavioral therapy or other psychotherapeutic treatments. 196 
Arguably, another clinically relevant finding was the greater OCD severity in patients with vs 197 
without BD comorbidity. Previous analyses showed mixed results in this respect 17,32. As the Y-198 
BOCS focuses exclusively on obsessions and compulsions, it is not likely that the higher scores 199 
would have been confounded by the presence of comorbid BD symptomatology per se. In fact, 200 
while obsessions might possibly determine higher scores due to concomitant depressive ruminations 201 
(though the two groups did not differ on depression scores) or flights of ideas, compulsions are 202 
relatively pathognomonic for OCD and OC related disorders. In our analysis, both the obsessive and 203 
the compulsive subscale scores, as well as the total score, were higher in the comorbid group, thus 204 
indicating a more severe OCD phenotype. Nonetheless, it must be borne in mind that OCD 205 
symptomatology is strongly influenced by mood phases 4,5, and consequently the latter might have 206 
determined an impact on YBOCS scores assessed in the present sample. 207 
Lastly, even though other statistically significant differences between OCD patients with vs without 208 
comorbid BD were not found, it is noteworthy to mention that current suicidal risk was almost 209 
twice as high in comorbid subjects. OCD is per se associated with a higher suicidal ideation and 210 
lifetime suicide attempts compared to the general population 33,34 and the comorbidity with BD 211 
might increase this phenomenon. Nonetheless, in our sample, the rates of previous suicide attempt 212 
were similar between the two subgroups, differing from a previous report showing a higher rate in 213 
comorbid OCD patients 15 and encouraging additional investigation on suicidal behaviors and risk 214 
in these patients. However, in this study, it needs to be noted that OCD patients without BD 215 
comorbidity could have a range of other comorbid disorders contributing to higher suicide attempt 216 
rates.  217 
Finally, focusing on a sociodemographic perspective, despite not reaching the statistically 218 
significant threshold, a divorced status, living alone, and being unemployed were observed at rates 219 
twice as higher in OCD patients with vs without comorbid BD. These findings also deserve further 220 
investigation, as they may converge in delineating a more disadvantaged sociodemographic 221 
condition of OCD patients when comorbid BD is present. 222 
The findings reported in the present study should be interpreted in light of some limitations. First, 223 
our study did not characterize BD phases at the assessment nor other issues related to BD polarity 224 
(i.e., polarity at onset or prevalent polarity) and subtype. These variables could have made our 225 
results easier to interpret, likely having a major impact on several clinical characteristics, including 226 
number of hospitalizations, pharmacological treatments, and YBOCS score. Additionally, OCD 227 
phenotype was not assessed in the total sample nor in the two subgroups and sample collection 228 
(mainly tertiary centers specialized in OCD) might have affected the results and influence their 229 
generalizations. Lastly, given the International nature of the study, specific variables were recorded 230 
only in a limited number of centers and consequently not analyzed due to the presence of missing 231 
data that did not allowed us to compare and contrast all variables. At the same time, the 232 
international sample assessed in the present study can be considered one of the strengths of this 233 
report. 234 
In conclusion, our results indicate that when OCD was comorbid with BD (6.2% of the cases), 235 
patients were found to show an overall higher severity of illness, as documented by a higher rate of 236 
hospitalization, a more complex pharmacological regimen, as well as a higher Y-BOCS score. 237 
Further studies are needed to verify the impact of BD comorbidity on OCD and to clarify the 238 
longitudinal relationship between these two disorders and their respective evolution. 239 
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